After initial breast cancer treatment, pharmacists can help patients navigate ongoing endocrine therapy, manage persistent adverse effects, and address medication concerns that affect long-term care.
|Articles|March 4, 2022
Daily OTC Pearl: BenGay
Author(s)Saro Arakelians, PharmD
Advertisement
OTC/Lifestyle Pearl of the Day: BenGay
Indication: BenGay offers relief from minor arthritis pain, backache, muscle and joint pain.
Insight:
- Available in 2 oz. and 4 oz.
- Directions: Adults and children 12 years of age and older apply to affected area not more than 3 to 4 times daily. For children under 12 years of age, consult ask a physician.
- Active ingredients: Camphor 4% (Topical analgesic), menthol 10% (topical analgesic), methyl salicylate 30% (topical analgesic).
- Inactive ingredients: Carbomer, disodium EDTA, glyceryl stearate SE, lanolin, polysorbate 80, potassium hydroxide, stearic acid, triethanolamine, and water.
- Storage: Store between 20º and 25ºC (68º and 77ºF).
Sources:
Advertisement
Related to this article
Parminder K. Judge, PhD, explains why eGFR and electrolytes should be monitored when diuretics are added to reach intensive BP targets in patients with CKD
The project maps how flu and HIV proteins enter cells, with the aim of developing longer-lasting vaccines.
Five breast cancer treatment advances in 2026 expand therapeutic options while raising questions.
VAX-31 met all primary end points against PCV20 and PCV21 in the pivotal phase 3 OPUS-1 trial.
Pharmacy teams can prevent early discontinuation by setting clear expectations for when—and how—a medication's benefit will become apparent.
The once-daily device, bioequivalent to the existing prefilled syringe, gives adults with AChR antibody-positive generalized MG a second self-injection option.
A year after FDA approval in heart failure (HF) with LVEF of 40% or higher, new ACC guidance and trial subanalyses are shaping how pharmacists use finerenone.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Finerenone Expands MRA Options as Pharmacists Address Underrecognized HFpEF
2
Diuretics, eGFR, and Intensive BP Lowering in CKD: What to Watch
3
Finerenone in Heart Failure: Evidence and Practice a Year Later
4
5 Breast Cancer Advances in 2026—And The Questions They Leave Unanswered
5